The respiratory disease drug developer has collected series A funding from investors including Shionogi to fund clinical trials of its lead drug candidate .
Vast Therapeutics, a US-based developer of respiratory disease therapies based on research at University of North Carolina (UNC) at Chapel Hill, has secured $15m in a series A round that included pharmaceutical firm Shionogi, Wral TechWire has reported.
The company revealed it had raised funding last month without giving a precise amount. It has also received a $300,000 award from non-profit organisation the Cystic Fibrosis Foundation to study the effects of chemical substances on living organisms.
Vast is…
